Molecular differentiation and specialization of vascular beds by Susana F. Rocha & Ralf H. Adams
REVIEW PAPER
Molecular differentiation and specialization of vascular beds
Susana F. Rocha Æ Ralf H. Adams
Received: 18 January 2009 / Accepted: 22 January 2009 / Published online: 12 February 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Transport in the large and complex bodies of
vertebrate organisms is mediated by extensive and highly
branched tubular networks that are formed by endothelial
cells. Blood vessels are responsible for systemic circula-
tion, while the lymphatic vasculature drains extravasated
plasma, proteins, particles, and cells from the interstitium.
Endothelial cells of blood vessels and lymphatic vessels
can be distinguished by the expression of certain molecular
markers, which accompany or even contribute to functional
and morphological differences. Even within the blood
vessel network, some molecules and pathways selectively
mark the endothelium of arteries, veins and capillaries and
are thought to contribute to the differentiation of these
vessels. Moreover, microvessels can acquire organ-specific
specialization in response to local tissue-derived signals.
This review summarizes molecular markers and pathways
that are specifically expressed in the endothelium of certain
vascular beds and vessel types. Special attention will be
given to known functional roles in the morphogenesis of
these vessels.
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Introduction
Until the late 90s, it was thought that the characteristic
features of arteries and veins were controlled by hemody-
namic forces, such as blood pressure and differences in
oxygenation. This idea was first challenged about a decade
ago with the description of the differential expression of
ephrin-B2 and of its receptor, EphB4, in embryonic arterial
and venous cells, respectively, even before the onset of
blood-flow and heart beat [1–3]. Since then, additional
arterial–venous (AV) markers have been identified (Fig. 1).
For instance, arterial cells are known to specifically express
the gap junction proteins Connexin-37 (Cx37) and Conn-
exin-40 (Cx40) [4–6], components of the Notch pathway,
such as Dll4 [7–9], as well as the VEGF co-receptor
Neuropilin-1 (NRP1) [10–12]. On the other hand, venous
cells specifically (or at least predominantly) express certain
members of the VEGF pathway, such as the co-receptor
Neuropilin-2 (NRP2) [10, 13, 14] and receptor VEGFR3
[15–17], COUP-TFII that negatively regulates the Notch
pathway [18], and the Apj receptor [19]. Nevertheless, it is
not fully understood to what extent some of these AV
markers are essential for the determination of the endo-
thelial cell (EC) fate. Indicating multiple functional roles in
the vasculature, several of these molecules are also
expressed in growing capillary beds and control endothelial
sprouting angiogenesis in addition to AV differentiation
(Fig. 1). It also remains to be resolved, to which extent
genetics and hemodynamic forces may act in an integrated,
interdependent fashion. For example, it has been shown
that shear forces derived from blood flow induce the
expression of transcription factors, such as Kru¨ppel-like
factor 2 (Klf2) and of its putative downstream targets [20–
22], thereby establishing a link between hemodynamic and
genetic regulation.
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Cellular processes contribution to AV differentiation
While it has been proposed that ECs committed to the
arterial or venous fate are already molecularly distinct in the
primitive vascular plexus of the yolk sac [1], arteries and
veins are formed from capillary ECs without apparent pre-
determined AV commitment in many other tissues (Fig. 2).
Here, arterial–venous differentiation involves the remodel-
ing of primitive capillary beds into a hierarchial network of
arteries, capillaries, and veins with distinct morphologies
and gene expression profiles. This also indicates that cap-
illary ECs possess a significant amount of plasticity and can
differentiate into venous or arterial endothelial cells
depending on their location within a remodeling vascular
bed. The detailed cellular and molecular processes that are
part of the AV remodeling program are incompletely
understood. However, since arteries have few side branches,
their differentiation from a dense capillary network has to
involve extensive pruning processes. Indeed, retraction
figures, i.e., local thinning and detachment of endothelial
connections, are abundant during early as well as later stages
of arterial morphogenesis [23] (Fig. 2). Signs of pruning can
be also seen around veins and even in capillary beds but are
less frequent when compared with the peri-arterial space. As
a consequence, one characteristic of arteries is that they are
surrounded by an almost completely avascular (i.e., capil-
lary-free) zone, which increases with arterial caliber and
probably indicates sufficient oxygenation of the peri-arterial
tissue [23] (Fig. 2). Another typical feature of arteries is
their slender and straight morphology (Fig. 2), which is
thought to be an adaptation to high flow speeds and local
shear stress [24, 25]. Conversely, developing veins appear
more irregular and have a larger diameter, features which
are also seen as a consequence of local hemodynamic
properties. At the same time, EC proliferation in capillaries
and veins is high when compared with the arterial endo-
thelium, which may, together with cell shape changes
(primarily EC elongation/stretching and parallel alignment),
contribute to the characteristic morphologies of developing
arteries and veins.
Differential recruitment and association of mural cells is
a further feature of the AV differentiation cascade [26–28].
Vascular smooth muscle cell (VSMC) coverage is more
pronounced on arteries and circumferential alignment of
these cells (perpendicular to the direction of blood flow) is
likely to maximize structural support given to the endo-
thelium [29–31]. Certain smooth muscle differentiation
markers, like the protein smoothelin which also directly
contributes to contractility, are expressed in VSMCs of
perinatal arteries but not in veins [32, 33]. Venous smooth
muscle cells are also less abundant and their alignment is
limited. Likewise, certain matrix proteins and elastic fibers
are predominantly or exclusively found in the arterial

















Fig. 1 Vessel-type specific
markers. Expression of selected
molecular markers in the
endothelium of an artery (red),
vein (blue) and lymphatic
vessels (green). While some
markers are expressed in a
strictly AV-specific fashion,
others extend into the capillary
network and have been linked to
angiogenic growth and
sprouting. VSMCs on blood
vessels (red/blue) and valve-
containing lymphatic collecting
ducts as well as pericytes
covering capillaries (yellow) are
indicated
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recruitment and differentiation features remain to be iden-
tified, but known regulators of mural cell recruitment,
such as platelet-derived growth factor B (PDGF-B) and
its receptor PDGFRb [26, 37], TGF-b and its receptors
[38–42], angiopoietin-Tie2 [43–45], and ephrin-B2 [46, 47],
are likely candidates. Likewise, vessel type-specific expres-
sion of Klf2, which is induced in response to blood flow-
derived shear forces, regulates VSMC migration as well as
vessel wall assembly, and thereby integrates hemodynamic
and genetic aspects of arterial differentiation [20–22, 48].
The many roles of VEGF signaling
The VEGF pathway is critical for blood vessel formation,
given its participation in a variety of vascular processes
including EC proliferation, migration, survival, and
arterial–venous cell fate specification [49, 50]. In mammals
there are several VEGF ligands (VEGF-A, B, C, D and E)
and receptors (VEGFR-1 to 3) that display distinct binding
affinities enabling VEGF signaling to yield distinct sig-
naling outputs and biological responses. VEGF signaling is
required for proper arterial–venous specification and,
accordingly, compromised VEGF (vegfaa) expression
leads to an arterial-to-venous cell fate switch in zebrafish
embryo [51]. While this first study focused on the role of
VEGF signaling in the induction of the arterial cell fate,
recent work has shown that the pathway is also required for
the inhibition of the arterial fate in cells committed to
venous differentiation [52]. How is VEGF signaling able to
act on both arterial and venous endothelial cells and trigger
distinct responses in each cell type?
The VEGF receptors show overlapping but distinct
expression patterns. VEGFR2 is expressed in most or all
endothelial cells, whereas VEGFR3 expression seems to be
excluded from arterial cells [16, 17]. Moreover, the VEGF
ligands display different binding affinities to each of the
receptors. VEGF-A is only able to bind receptors VEGFR-
1 and 2, while VEGF-C and D have higher affinities for
VEGFR-3. Additionally, it is known that VEGF-A-medi-
ated signaling is more efficient in activating phospholipase
C-gamma (PKC-c) and its downstream signaling partner,
the mitogen-activated protein kinases (MAPKs) Erk1 and
2. In contrast, VEGF-D induces a strong activation of the
protein kinase Akt through phosphatidylinositol 3-kinase
(PI3K) [53]. The ligand VEGF-C is a potent activator of
both MAPK and Akt [54].
Recent studies in zebrafish have shown that these two
downstream targets of VEGF signaling, PKC-c/ERK and
PI3K/Akt, have distinct roles in arterial [55, 56] and
venous differentiation [52]. PLC-c1/Erk signaling induces
proliferation and specification of arterial endothelial cells
[55, 57], while PI3-K/Akt signaling inhibits PKC-c/MAPK
activation in cell culture and in zebrafish and thereby
blocks the acquisition of the arterial cell fate [52]. Thus,
the VEGF pathway participates in arterial–venous specifi-
cation by differentially regulating the activation of
downstream targets in arterial and venous cells.
Despite the striking evidence for distinct functional roles
of VEGF-triggered signaling, it is still difficult to under-
stand how certain downstream signal transduction cascades
get selectively activated in response to VEGF–VEGFR
interactions. Thus, it is likely that additional players, such
as Neuropilin family (NRP) molecules, can further modu-
late the final output of VEGF signaling. NRP1 and NRP2
are transmembrane glycoproteins that function as non-
signal transducing co-receptors of VEGF. NRP1 forms a
co-receptor complex with VEGFR-2 and thereby enhances
the binding affinity of VEGFR-2 to a specific isoform of
VEGF-A (VEGF164), which plays a pivotal role in vas-



















Fig. 2 Processes during AV remodeling. Schematic representation
(based on a real isolectin B4 staining of retinal blood vessels) of
cellular processes in growing vascular beds. Higher magnifications of
insets show pruning processes during arterial development (red
boxes) and features of the venous circulation (blue)
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lethal at midgestation due to defects in vascular remodeling
of the yolk sac and impairment in the development of
aortic arches and large vessels [58]. EC-specific deletion of
NRP1 leads to the loss of specific arterial markers, such as
ephrin-B2 and Connexin40 [59]. Knockout mice lacking
NRP2 are viable and display axon guidance defects, but not
any overt blood vessel phenotype [60, 61]. However, the
formation of the lymphatic vessels is impaired in these
mutants [14]. NRP2 expression in venous and lymphatic
ECs mimics that of VEGFR-3. Indeed, VEGF-C and D
have been shown to bind to NRP2, which enhances VEGF
receptor signaling in cultured cells and lymphangiogenesis
in tumors [62–64].
Notch signaling and arterial–venous specification
Notch signaling is an evolutionarily conserved pathway that
is involved in a wide range of biological processes including
cell fate determination, proliferation, and survival [65, 66].
Signaling through the Notch pathway occurs through direct
cell–cell communication and is mediated by contact-
dependent receptor and ligand interactions. In mammals,
there are four distinct Notch receptors (Notch1-4) and five
ligands that belong to the Delta (Delta-like 1, 3 and 4) or
Jagged/Serrate protein families (Jag1 and Jag2). The anal-
ysis of Notch mutants has shown that the pathway is
required for cell fate decisions, a well-known role in other
systems such as the nervous system. Likewise for VEGF
loss-of-function mutants [51], compromised Notch activity,
both in mouse and zebrafish, has uncovered an important
role in establishing the arterial cell fate [17, 67–70]. In
addition, the Notch pathway also regulates sprouting angi-
ogenesis through the ‘selection’ of tips cells at the
angiogenic front [71–75]. The similarity between the phe-
notypes observed in mutants of the VEGF and Notch
pathway suggests tightly controlled, interdependent regu-
latory relationships. Notch has been shown to act
downstream of VEGF, since ectopic activation of Notch in a
VEGF mutant background is sufficient to rescue vascular
defects in zebrafish embryos [51]. Specifically, the Dll4
ligand, which is expressed exclusively in arterial ECs and
angiogenic capillary beds, and the Notch1 receptor have
been identified as downstream targets of VEGF signaling
[75, 76]. On the other hand, downregulation of VEGFR-2
and VEGFR-3 expression and upregulation of the antago-
nistically acting receptor VEGFR-1 are critical downstream
responses to Notch activation in ECs [16, 71, 72, 74].
Recent in vitro work has shown that VEGF-mediated
regulation of Notch occurs through transcription factors of
the forkhead family, Foxc1 and Foxc2, which bind to the
promoters of Dll4 and Hey2. The latter is a direct down-
stream target of Notch signaling in the vasculature and is
involved in the regulation of gene transcription in response
to Notch activation [77, 78]. Although the expression of
Foxc1 and Foxc2 is not restricted to arterial ECs [77], it has
been shown that the activity of these transcription factors is
augmented by VEGF-activated Erk signaling in cultured
cells. In contrast, PI3K signaling inhibits Foxc-mediated
activation of the Dll4 and Hey2 promoters [78]. However,
these results seem to be at odds with the higher levels of
PLC-c1/Erk signaling reported for the zebrafish aorta [52],
which should block the activity of Foxc transcription fac-
tors, and suggests that additional modes of regulation may
exist.
The activity of Foxc1/c2, VEGF and Notch are known
to promote the expression of arterial markers such as
ephrin-B2 and Cx40, whereas the orphan nuclear receptor
COUP-TFII (also known as NR2F2) has been identified as
the first positive regulator of venous endothelial identity
[18]. While COUP-TFII is present in both ECs and mural
cells, endothelial expression is restricted to veins and
excluded from arteries. COUP-TFII knockout embryos are
lethal at day 12 after fertilization and exhibit a phenotype
opposite to that observed upon loss of Notch activity: a
partial loss of the venous cell fate indicated by reduced (but
not completely absent) EphB4 expression, together with
the ectopic expression of arterial markers, such as Dll4 and
ephrin-B2 [18]. Ectopic expression of COUP-TFII in
transgenic mice can suppress the expression of arterial
markers in the dorsal aorta [18]. Although the mechanism
through which COUP-TFII acts is not completely under-
stood, its negative effect on Dll4 and NRP1 expression is
likely to locally alter Notch as well VEGF signaling
responses during the regulation of AV differentiation.
Tissue-specific specialization of blood vessels
The example of veins and arteries shows that ECs can dif-
ferentiate into specialized subpopulations with characteristic
gene expression profiles. Specific morphological and func-
tional features of blood vessels in certain organs suggest the
existence of an even larger degree of heterogeneity among
ECs in terms of gene expression and signaling pathways. For
example, the endothelium of endocrine glands, pancreas,
intestine, kidney glomeruli and liver sinusoids contain small
(60–70 nm in diameter) but densely clustered pore-like
openings termed fenestra, which increase local permeability
and are thought to facilitate the exchange between the
circulation and the surrounding tissue. Some endothelial
fenestrations contain a diaphragm, a central structure with
wheel spoke-like extensions that subdivide the pore into
several smaller openings. The type II membrane glycopro-
tein PV-1 (Plasmalemmal vesicle associated protein-1) is a
molecular component of diaphragms, and it is both necessary
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and sufficient for diaphragm formation in cultured ECs [79,
80]. Anti-PV-1 immunofluorescence marks blood vessels
containing diaphragmed fenestra, but is also present in some
non-fenestrated vascular beds. Conversely, PV-1 is absent
from certain fenestrated blood vessels (such as liver sinu-
soids) presumably because they lack diaphragms [81, 82].
Although very little is known about the formation of
fenestra, it has been shown that their formation can be
induced by VEGF-A [83–85] as well as endocrine gland
vascular endothelial growth factor (EG-VEGF), a special-
ized and tissue-specific angiogenic molecule [86]. Further
linking endothelial fenestrations to VEGF signaling, inhi-
bition of VEGF activity in mice leads to the reduction of
fenestrations and, concomitantly, the partial regression of
capillaries in tissues containing fenestrated vascular beds
[87–90]. This role of VEGF may also explain the appear-
ance of ectopic endothelial fenestrations in the vasculature
of tumors and in other pro-angiogenic disease settings [89,
91–93].
While endothelial fenestrations are associated with high
permeability, the endothelium of the central nervous system
forms a barrier (termed the blood–brain barrier, BBB) that
tightly controls trans-endothelial transport and cell migra-
tion [94]. Continuous strands of tight junctions (TJs)
containing claudin and occluding family membrane-span-
ning proteins seal brain ECs and thereby strictly limit the
paracellular transport route. Enabling necessary transport
across the BBB, ECs express specific transporters for
glucose, amino acids, and other substances. The important
role of the blood–brain barrier is emphasized by its break-
down in human diseases. For example, immune cells gain
access to the normally immunoprivileged brain tissue and
trigger harmful inflammatory processes in the autoimmune
disease multiple sclerosis [94].
Recent work has established that the formation of the
BBB during development is controlled by canonical Wnt
signaling [95, 96]. Wnt7a/b double mutants or embryos
lacking endothelial expression of b-catenin display exten-
sive hemorrhaging and reduced vascularization of the CNS.
The glucose transporter GLUT-1, a BBB marker, is
downregulated in these mutant embryos, whereas ectopic
expression of Wnt7a is sufficient to induce GLUT-1-positive
ECs outside the CNS [96]. A second and independent study
that focused on postnatal formation and maturation of
the BBB confirmed that endothelial b-catenin promotes
Claudin-3 (Cldn3) expression and suppresses expression of
PV-1 (in this study termed Pvlap), which is low/absent in the
normal BBB endothelium but gets ectopically upregulated in
mutant mice [95]. Furthermore, the authors show that Wnt3a
can upregulate Cldn3 levels in cultured ECs in a b-catenin-
dependent fashion. Both studies imply canonical Wnt sig-
naling and multiple Wnt genes in the formation of the BBB.
Future work will have to address if Wnt signaling is also
required for the maintenance of the BBB and whether
activation of the pathway might be an approach to restore
compromised barrier function in disease settings.
Regulation of lymphatic endothelial cell identity
Despite the fact that lymphatic ECs in the mouse are derived
from venous ECs during embryonic development [97], the
lymphatic endothelium expresses a set of specific genes that
are not found on blood vessels (Fig. 1) [98, 99]. When
morphogenesis of the lymphatic vasculature is initiated,
differentiation of the first lymphatic ECs (LECs) in the
cardinal vein can be detected by the expression of the
homeobox-containing transcription factor Prox1 (prospero-
related homeobox gene 1) (Fig. 3). Prox1 is the master reg-
ulator of LEC differentiation and induces the expression of a
battery of LEC-specific genes, while other genes, which are
characteristic for the blood vessel endothelium, get sup-
pressed [98–100]. In mice lacking Prox1, LEC differentiation
fails and no lymphatic vasculature is formed [100].
Recently, it has been shown that the role of Prox1 is not
confined to lymphatic development in the embryo,
but actually extends into adulthood. Tamoxifen-inducible

















Sox18:      induction of lymphatic differentiation
Prox1:       lymphatic differentiation and maintenance





Fig. 3 Induction of the
lymphatic vasculature.
Expression of Sox18 in selected
venous ECs triggers the
expression of the lymphatic
master regulator Prox1. Prox1
induces expression of other
markers and regulators of the
lymphatic vasculature such as
VEGFR-3, which controls LEC
proliferation, migration and
numerous other aspects of
lymphangiogenic growth
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the Prox1 gene at various embryonic or postnatal stages
leads to lymphatic vessel defects, prominent edema and
the downregulation of LEC markers like podoplanin,
CCL21/SLC and LYVE-1 [101]. At the same time,
endoglin or CD34, markers characteristic for blood vessel
ECs (BECs), are upregulated and mutant lymphatic capil-
laries (initial lymphatics) acquire an ectopic coverage by
a-smooth muscle actin-positive perivascular cells reminis-
cent of the mural coverage of blood vessels [101]. The
surprising conclusion that continued Prox1 expression is
required to maintain LEC differentiation raises the question
whether lost expression or dysfunction of Prox-1 might be
linked to human pathologies, particularly to settings where
lymphatic vessels are compromised or ECs lack a clear
BEC/LEC identity [102–104].
Another important task will be the identification of fac-
tors required for the induction or maintenance of Prox1
expression. In the early embryo, one such upstream regu-
lator is the transcription factor Sox18 [105] (Fig. 3).
Dominant negative mutations of the Sox18 gene in naturally
occurring mouse mutants of the ragged allelic series cause
chylous ascites and edema. Likewise, dysfunction of the
Sox18 gene is linked to the hypotrichosis-lymphedema-tel-
angiectasia syndrome in humans [106]. While homozygous
Sox18-deficient mice in a mixed 129/CD1 background do
not display vessel defects, perhaps due to genetic compen-
sation by the related Sox family members Sox7 and Sox17,
knockout mice in a purebred C57/Bl6 background have been
recently found to develop lethal fetal edema [105]. Like
Prox1, Sox18 is also expressed in an EC cluster within the
cardinal vein and even precedes the onset of Prox1 expres-
sion by a whole day. Explaining the lymphatic defects seen
in Sox18 mice, no induction of Prox1-positive ECs occurs in
the cardinal vein of these mutants. Conversely, forced
expression of Sox18 in culture differentiating, embryonic
stem cell-derived ECs induces the upregulation of Prox1 and
other lymphatic signature genes. Indicating that Sox18 is a
direct regulator of Prox1 transcription, two Sox18 binding
sites in a proximal 4.1 kb Prox-1 promoter fragment are
necessary for Prox-1 expression in vitro and in vivo [105].
Despite the important role of Sox18 for the specification
of the first LECs, the absence of vascular defects in Sox18-
deficient mutants in the mixed 129/CD1 background and
expression of the gene in a fraction of embryonic blood
vessels argue against a mandatory and general role of
Sox18 as an inducer of Prox1 expression and therefore
additional upstream regulators are likely to exist.
Perspectives
The examples above show how recent progress has pro-
vided us with an increasingly complex picture of the
vasculature. Far from forming simple, blood-transporting
tubes that are shaped by flow, ECs undergo a series of
differentiation steps in response to intrinsic genetic pro-
grams as well as local tissue-derived signals. Future work
will identify further markers that allow us to distinguish
different vascular beds and vessel types. As the examples
of Prox1 and the Notch pathway show, some of these
molecules might be even key regulators of EC differenti-
ation processes. Unraveling of the genetic heterogeneity of
signaling pathways in different vascular beds, vessels or
even individual ECs will further improve our understand-
ing of how the morphogenesis of the vasculature and
organ-specific specialization processes are regulated. These
findings may well help to explain changes in human
pathologies and offer vital clues for the development of
therapeutics. The large degree of plasticity of endothelial
cells, which allows growth on demand after long periods of
quiescence as well as differentiation/de-differentiation
processes, suggests a significant potential for therapeutic
interference even in the fully developed, adult organism.
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